US/UK/Canada

Share

Contacts

  • Hansa Biopharma AB
    Scheelevägen 22 22363 Lund, Sweden
    +46 (0) 461 656 70
    http://www.hansabiopharma.com
    • Pick a time period -
    Tags ( Active)

    Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York

    Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, at 8:45 AM EDT on Thursday, June 4, 2026. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Fireside chat at Jefferies Global Healthcare Conference Date, Time, and Place: Thursday June 4, 8:45-9:15 AM EDT, at the Marriott Marquis in New York Speaker: Renée Aguiar-

    Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

    Lund, Sweden, June 1, 2026. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), has today on June 1, 2026 held its Annual General Meeting. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting of Hansa passed the following resolutions. Resolution regarding the adoption of the income statement and the balance sheet as well as consolidated income statement and consolidated balance sheet, appropriation of result and discharge from

    Hansa Biopharma’s CEO Renée Aguiar-Lucander named one of Sweden’s Most Influential Business Women of 2026

    Lund, Sweden, 29 May 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today are proud to announce that Renée Aguiar-Lucander, CEO, Hansa Biopharma has been named one of Sweden’s Most Influential Business Women of 2026 by Dagens industri. This nomination recognizes leaders with significant influence over the development, competitiveness and future of Swedish business. The award reflects both individual leadership and the role Hansa Biopharma plays in driving growth, innovation and competitiveness. Renée Aguiar-Lucander, CEO, said: “I am truly honored to be named as part of

    Hansa Biopharma reports positive efficacy and safety results from Idefirix[®] European post authorization study in kidney transplantation

    · The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission · Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience · Submission to EMA for conversion to full marketing authorization planned for Q4 2026Lund, Sweden, May 27, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year

    Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

    Lund, Sweden, May 25, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026. The presentation will include detailed 12-month results from the ConfIdeS trial, including the primary endpoint eGFR, key secondary endpoints as well as safety results. The presentation will be delivered by Dr Robert Montgomery, MD PhD, New York University

    Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

    · The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region · Significantly enhances Hansa’s financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval · SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercializationLund, Sweden, May 19, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and SERB S.A. (“SERB”) today announced an exclusive licensing agreement for development and

    Hansa Biopharma participating at LSX Nordic Congress

    Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Panel Discussion at LSX Nordic Congress Title: Scaling Success: Key Drivers for Growing Nordic Biotechs Date, Time, and Place: Tuesday 19

    Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

    Lund, Sweden, 12 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq in New York, from 17:00-17:30 EDT, on Tuesday 19 May, 2026. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, Hansa Biopharma Fireside Chat Date, Time, and Place: Tuesday 19 May,

    Notice to Annual General Meeting in Hansa Biopharma AB (publ)

    Lund, Sweden April 28, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gives notice to Annual General Meeting to be held on Monday June 1, 2026 at 14:30 CEST, Elite Hotel Ideon, Scheelevägen 27, SE-223 63 Lund. Registration starts at 14:00 CEST.Right to participate in the Annual General Meeting and notice of participation Participation in the Annual General Meeting at the venue A shareholder who wishes to participate in the Annual General Meeting at the venue in person or represented by a proxy must (i) be recorded as a

    Hansa Biopharma Report First Quarter 2026 Financial Results

    · PDUFA target date set for December 19 by the FDA · Runway significantly extendedLund, Sweden, 23 April 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report January-March 2026. Renée Aguiar-Lucander, CEO, Hansa Biopharma said, “In the first quarter of 2026, we continued to execute against our strategic priorities as we advanced imlifidase toward a potential U.S. approval of our Biologics License Application (BLA) with an assigned December 19 PDUFA[*] target date. Preparations for a potential U.S. launch progressed in parallel, while in

    Hansa Biopharma to host Q1 2026 interim results conference call

    Lund, Sweden, 8 April, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - March 2026 on 23 April, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company’s interim financial results and provide a business and pipeline update. The presentation will be held in English. Slides used in

    Hansa Biopharma publishes 2025 Annual and Sustainability Reports

    Lund, Sweden, 26 March 2026. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: “2025 was a year of transformation for Hansa Biopharma, marked by the appointment of Renée Aguiar‑Lucander as our new CEO with a clear mandate to reshape the company for sustainable growth. Under her leadership, we strengthened our foundations by improving our financial resilience and assembling a substantially new leadership team of proven, high‑performing leaders. At

    Hansa Biopharma announces a USD 30 million convertible note financing

    Lund, Sweden, March 20, 2026. Hansa Biopharma AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa” or the “Company”) today announces that it has entered into a U.S. convertible note purchase agreement with certain funds managed by Athyrium Capital Management (“Athyrium”), comprising USD 30 million aggregate principal amount of unsecured convertible senior notes (the “Financing”). The Financing extends the Company’s runway into mid 2027 and ensures a robust launch of imlifidase in the US, subject to approval.The Financing consists of unsecured convertible senior notes with an aggregate principal

    Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science

    Lund, Sweden, 13 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will be presenting at Redeye Theme Event: Commercialization in Life Science in Stockholm, at 10:15 AM CET on Friday 20 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending the event. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Redeye Theme Event: Commercialization in Life Science, Hansa Biopharma Corporate

    Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026

    Lund, Sweden, 10 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at DNB Carnegie Healthcare Conference 2026 in Stockholm, at 15:10 PM EDT on Thursday 12 March, 2026. Hansa Biopharma VP Global Corporate Affairs Kerstin Falck will also be attending the event. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: DNB Carnegie Healthcare Conference 2026, Hansa Biopharma Fireside Chat Date, Time, and

    Hansa Biopharma participating at LSX Investival Showcase USA

    Lund, Sweden, 9 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be participating in a panel discussion titled “The Path to Public: Mastering Your Exit Strategy” at LSX Investival Showcase USA in Miami, at 15:15 PM EDT on Tuesday 10 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will also be attending the event. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Panel Discussion at

    Hansa Biopharma participating at Leerink Global Healthcare Conference

    Lund, Sweden, 6 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at Leerink Global Healthcare Conference in Miami, at 13:40 PM EDT on Monday 9 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will also be attending the event. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Leerink Global Healthcare Conference, Hansa Biopharma Fireside Chat Date,

    PDUFA Action Date for Hansa Biopharma’s Imlifidase BLA Set for December 19, 2026

    · If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation.Lund, Sweden, 4 March 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “With the PDUFA date now set, we are one step closer to

    Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference

    Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at TD Cowen’s 46th Annual Health Care Conference in Boston, at 11:10-11:40 AM EST on Monday 2 March, 2026. Hansa Biopharma CFO Evan Ballantyne, and COO and President U.S. Maria Törnsén, will also be attending the event. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: TD Cowen 46th Annual Health Care Conference, Hansa Biopharma Corporate

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA

    Lund, Sweden, 18 February 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA). FDA's filing review was completed on day 60 which is meant to verify that the submission is substantially complete and meets the requirements for a full evaluation. Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “We now look forward to receiving the 74-Day Letter which will provide details regarding review plan, timelines and other

    Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    · Strong Q4 with 76.0 MSEK in revenue, up 135% from Q4 2024. · Submission of Biologics License Application (BLA) for imlifidase for highly sensitized patients awaiting kidney transplantation. · Successfully completed a directed share issue raising 671.5 MSEK (~ $71.3M).Lund, Sweden, 11 February 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its Q4 2025 and full-year financial results. Renée Aguiar-Lucander, CEO, Hansa Biopharma said, “Q4 capped a strong year for Hansa Biopharma. Filing our BLA with the FDA just three months after announcing Phase 3

    Hansa Biopharma to host Year-end report 2025 conference call

    Lund, Sweden, 26 January, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its year-end report for January - December 2025 on Wednesday 11 February, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CET / 8:00 AM EST. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company’s year-end financial results and provide a business and pipeline update. The presentation will be held in

    Hansa Biopharma has won the 2025 SwedenBIO Award

    Lund, Sweden, 22 January 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm on 21 January, where Hansa was selected as the winner among the many nominated companies. Since its inception in 2007, the SwedenBIO Award has celebrated companies that drive meaningful scientific progress, operational excellence, and international impact. This year’s motivation highlights Hansa Biopharma for transforming Swedish scientific excellence into

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media